Athenex and SunGen Pharma have entered an agreement to form a joint venture to market their value products in the US.

According to the agreement, the newly formed joint venture company will be the marketing and sales arm of SunGen Pharma in the US and will be responsible for marketing the Athenex pipeline products.

The agreement enables Athenex to launch its new products in the US market.

PapGene and National Cancer Institute have entered a fast-track, small business innovation research contract to develop a new test to identify recurrent bladder cancer.

"PapGene and National Cancer Institute have entered a fast-track, small business innovation research contract to develop a new test to identify recurrent bladder cancer."

According to the agreement, the funding for the contract will be provided in two phases to demonstrate the accuracy and clinical utility of the test, as well as for its commercialisation.

The agreement enables PapGene to commercially develop a test to identify recurrent bladder cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ironwood Pharmaceuticals has completed debt refinancing by raising $150 million through 8.375% notes, due September 2026. The offering has been subscribed to by institutional investors affiliated with TSSP.

The company will use the funds to pay the remaining balance of Linaclotide PhaRMASM 11% notes, due 2024.

EPS Holdings plans to raise $405 million through the private placement of 3,500 shares of its common stock.

Suzuken Co. will subscribe to the shares to become a 35% stake holder in EPS Holdings.

MicuRx Pharmaceuticals has raised gross proceeds of $55 million in a series C financing led by GP Healthcare Capital along with GP TMT Capital limited, 3E Bioventures Capital and Delian Capital.

The company plans to invest the funds for the development of MRX-I within the US and China markets.